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ated with dose intensity of radiosensitizing Doc, and was diminished 
by dose reduction. Results suggest that this regimen should be further 
evaluated for stage III NSCLC. The PK disposition of Doc was similar 
at full-dose (75 mg/m2) and at low-dose (10 mg/m2 or 12 mg/m2) for 
Doc plasma clearance and half-life. Doc PK was not affected by the 
presence of cisplatin during induction CT. 
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Lung cancer in women: results of treatment
Cicenas, Saulius; Valuckas, Konstantinas P.; Aleknavicius, Eduardas; 
Aleknaviciene, Birute; Pipiriene, Terese; Askinis, Renatas; Kurtinaitis, 
Juozas 
Institute Oncology, Vilnius University, Vilnius, Lithuania
Background: Evaluate efﬁcacy of combined surgical and conservative 
treatments women lung cancer in Lithuania. 
Matherial and Methods: From 1996-2003 y.y. 316 patients (women) 
entered study evaluating results of lung cancer treatment in Institute of 
Oncology, Vilnius University. Patients were stratiﬁed according: age, 
stage of disease, smoking status, morfology and treatment (surgery 
alone or with other treatment v/s no surgery involved). According age 
patients distribution were: 35-49 y. - 43 pts (13,6%), 50-64 y. - 124 
pts (39,2%), 65-74 y. - 108 pts (34,1%) and 75+ y. - 41 pts (12,9%). 
Morfology: adenocarcinoma - 173 pts (54,7%), epidermoid - 43 pts 
(13,6%), SCLC - 31 pts (9,8%), carcinoid - 9 pts (2,8%), cancer cells 
- 19 pts (6,0%) and nonclassiﬁed carcinoma - 41 pts (12,9%); By stage: 
I stage - 55 pts (18,4%), II stage - 66 pts (20,8%), III stage - 100 pts 
(31,6%), IV stage - 95 (30,1%); By smoking status: non smokers - 241 
pts (76,2% ), smokers - 75 pts (23,7% ). Surgery was performed in 85 
pts (26,9%), combined surgical treatment - 61 pts (19,3%), combined 
conservative treatment - 103 pts (32,6%), 67 pts (21, 2%) received 
palliation. 
Results: overall 5 years survival 23% of cases. 5 years survival by age: 
<50 y. - 18%, 50-64 y. - 20%, 65-74 y. - 19%, +75 y. - 17% cases. 5 
years survival by stage: I stage - 52%, II stage - 25%, III stage - 10%, 
IV stage - 12%. 5 years survival by morfology: adenoCa - 22%, epider-
moid - 22%, SCLC - 10%, carcinoid - 52%, cancer cells - 22%, non-
classiﬁed carcinoma - 24%. 5 years survival by smoking status: SCLC: 
smokers 5 %, non smokers - 15%; nonclassiﬁed carcinoma: smokers 
- 0%, non smokers - 26%. 5 years survival estimate by treatment: 5 
years survival: surgery±combined treatment 25% of cases, no surgery 
involved - 10% of cases. 
Conclusions: 1. Surgical or surgical combined treatment was superior 
to conservative treatment (5 years survival 25% v/s 10%). 2. Bet-
ter treatment results were achieved in carcinoid treatment (5 y. surv. 
- 52%), NSCLC - 22%, SCLC - 10% and nonclassiﬁed carcinomas 
- 24%. 3. Overall 5 y. survival in women lung cancer in this study was 
achieved in 23% of cases. 
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Induction chemotherapy versus induction chemoradiotherapy for 
pathological N2 non-small cell lung cancer
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Background: Several studies have suggested that induction therapy 
followed by surgical resection may improve the outcome in patients 
with stage IIIa (N2) non-small-cell lung cancer (NSCLC), however, 
optimal induction strategy has not been deﬁned. 
Methods: We retrospectively reviewed the medical records of 33 
patients with stage IIIa NSCLC having mediastinal lymph node metas-
tases proved by mediastinoscopy. Fifteen patients received induction 
chemotherapy (CT) between 1995 and 1999. Eighteen patients received 
induction chemoradiotherapy (CRT) between 2000 and 2006. For 
induction CT, CDDP (60 mg m-2) and CPT-11 (50 mg m-2) were given 
on days 1, 8, 29, and 36. For induction CRT, cisplatin (40 mg/m2) and 
docetaxel (40 mg/m2) were given on days 1, 8, 29, and 36 along with 
concurrent thoracic irradiation at a dose of 46 Gy (2 Gy/fraction/day). 
Induction was followed by surgical resection in 4-6 weeks.
Results: Preoperative patients’ characteristics were similar between 
CT and CRT (Table 1). All 33 patients underwent surgical resection 
after the induction therapy. The rate of pathological effectiveness of 
the main tumor (the rate of Ef2 or Ef3) was signiﬁcantly higher in 
CRT than in CT (72.2% vs 26.7%, p = 0.022). Treatment related death 
was encountered in one CT patient but in none of CRT patients. The 
5-year survival rate was signiﬁcantly better in CRT (68.2%) than in CT 
(26.7%) as shown in Figure 1.
Conclusions: Induction CRT may provide signiﬁcantly better patho-
logical effectiveness than induction CT, thus may improve the survival 
for patients with stage IIIa (N2) NSCLC. 
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ERCC1 and Beta Tubulin III (BTUB) isoform expression by 
Immunofluorescence (IF) may correlate with survival after 
combined modality therapy (CMT) for stage III NSCLC
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Background: Multimodality therapy has clearly improved outcome 
in Stage III NSCLC. However, the majority of patients still succumb 
to disease. Platinum based therapy, utilized both concurrently with 
radiotherapy as well as induction/consolidation therapy is central to 
this approach. Recent data in adjuvant therapy and in stage IV disease 
indicate that ERCC1 expression correlates with platinum responsive-
ness. BTUB isoform expression has been correlated to sensitivity to an-
titubulin agents. We utilized a novel, quantiﬁable, IF method to assess 
ERCC1 and beta tubulin III expression in pre-treatment specimens and 
correlated with overall survival from a prospective institutional study.
Methods: Pts with path III A/B disease, PS 0-1 were eligible. CMT 
consisted of induction therapy with escalating doses of Carboplatin 
(C)(AUC=1), and Vinorelbine (V) 5-15mg/m2 q wk, with concurrent 
69.6 Gy (1.2 Gy bid/5 d/wk for 29 d). Pts with negative mediasti-
nal nodes after chemoXRT underwent resection, if feasible. All pts 
received additional chemoRx consisting of C/V at AUC=5 d1, 25mg/m2 
d1,8 q 21 d X 3 followed by docetaxel 75mg/m2 2 q 21 d x 3. Parafﬁn 
embedded tumor specimens were analyzed by IF staining for ERCC1 
and BTUB. Anti-ERCC-1 was directly labeled with Alexa 594 while 
anti-beta-tubulin was counterstained with Alexa 532 dye. IF was 
measured quantitatively with a computerized microscopy system and 
expressed as the mean of the average ﬂuorescence per pixel. IF expres-
sion in the tumor sections is measured in 1000 tumor cells utilizing 5 
